Kim Ja Kyung, Hahn Jee Sook, Kim Gwi Eon, Yang Woo-Ick
Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea.
Yonsei Med J. 2005 Oct 31;46(5):703-9. doi: 10.3349/ymj.2005.46.5.703.
Primary splenic lymphoma (PSL) is often defined as generalized lymphoma with splenic involvement as the dominant feature. It is a rare disease that comprises approximately 1% of all malignant lymphomas. We investigated three cases of non-Hodgkin's splenic lymphoma that had different clinical features on presentation. The patients' survival times from diagnosis ranged from 59 to 143 months, without evidence of relapse after splenectomy and chemotherapy, with or without radiotherapy. This data suggest that PSL is potentially curable. Further studies are needed to evaluate the impact that different treatment modalities without splenectomy have on patient survival.
原发性脾淋巴瘤（PSL）通常被定义为以脾脏受累为主要特征的全身性淋巴瘤。它是一种罕见疾病，约占所有恶性淋巴瘤的1%。我们调查了3例非霍奇金脾淋巴瘤病例，这些病例在临床表现上具有不同特征。患者从诊断开始的生存时间为59至143个月，在接受脾切除和化疗（无论是否接受放疗）后均无复发迹象。这些数据表明PSL可能是可治愈的。需要进一步研究来评估不进行脾切除的不同治疗方式对患者生存的影响。
